- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Researchers are investigating microneedles, nanoparticles and polymer carriers as potential new techniques to combat the leading cause of visual impairment and blindness in the United States, according to a report from the Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.
The report (www.iovs.org/cgi/content/full/49/11/4712) includes summaries from seven sessions on techniques for ocular drug delivery to the posterior segment of the eye and includes the findings of and opinions of more than 30 top ophthalmic researchers, brought together by the ARVO Foundation for Eye Research. The article in the November issue of Investigative Opthalmology & Visual Science defines the current research and the future needs for ocular drug delivery.
Diseases of the posterior segment of the eye are responsible for the majority of visual impairment and blindness cases in the United States, according to George Williams, MD. Until recently, these diseases were primarily treated with surgery, but recent developments in drug therapies have either replaced or complemented surgery.
But the challenge lies in delivering the drugs. Topical delivery such as ointments and drops are fairly ineffective, and delivery via intravitreous injection (an injection into the fluid in the behind the lens in the eye) can be hard on the patient. According to the report, "Improved drug delivery technologies that provide optimal pharmacokinetics, dose intervals and less invasive routes of administration are needed."
During the two-day event, John Heckenlively, MD, joined Jayakrishna Ambarti, MD, in a session on animal models of posterior ocular diseases. Allan Hoffman, ScD, discussed the design of polymer carriers for intracellular delivery of biomolecular drugs, such as peptides, proteins and nucleic acid drugs. His group is focused on using a family of acid-sensitive polymers to help deliver one of the latest drugs, silencing RNA (siRNA).
Another group of presenters discussed the use of nanoparticles, microbeads and microneedles. Mansoor M. Amiji, PhD, said that nanoparticles can help overcome barriers to drug delivery from the organ level to the subcellular level. Another research laboratory was investigating the effectiveness of hollow and solid microneedles that penetrate only hundreds of micrometers into the cornea or sclera to deliver drugs.
A safer alternative to direct intravitreous injections might be transscleral delivery into the vitreous using subconjunctival injections, said Michael Robinson, MD, adding that researchers needed a clear understanding of the dynamic barriers for the technique to work in treating retinal diseases. Another researcher in this area, Dayle H. Geroski, PhD, suggested that the relatively high permeability of the sclera offers great potential for transscleral drug delivery, especially for administration to the posterior part of the eye.
Other research focused on photodynamic therapy, which uses a photosensitizer agent that localizes more or less selectively to the target tissue and is activated by light, triggering chemical reactions that injure the target tissue.
Drug Delivery to Posterior Intraocular Tissues:
Third Annual ARVO/Pfizer Ophthalmics Research
May 4-5, 2007, Fort Lauderdale, Florida
Session I: Unmet Needs and New Drug Opportunities in Treating Disorders of the Posterior Segment
Session II: Animal Models of Posterior Ocular Diseases
Session III: New Drug Design and Delivery Systems: What Do Experts See Beyond the Horizon?
Session IV: Ocular Drug Delivery Using Nanoparticles, Microbeads and Microneedles
Session V: Transscleral, Intravitreous and Suprachoroidal Drug Delivery
Session VI: Ocular Tissue Dissection, Modeling, and Ocular Tissue Assays
Session VII: Iontophoresis, Electroporation, Electrophoresis and Photo-acoustic Delivery
Henry F. Edelhauser, Jeffrey H. Boatright, John M. Nickerson and the Third ARVO/Pfizer Research Institute Working Group. Drug Delivery to Posterior Intraocular Tissues: Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest. Ophthalmol. Vis. Sci. 2008;49: 4712-4720.
About Association for Research in Vision and Ophthalmology
ARVO is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 70 countries. The Association encourages and assists research, training, publication and dissemination of knowledge in vision and ophthalmology. The ARVO Foundation for Eye Research exists to provide continuing education and stable support for original and innovative vision research, particularly research with translational impact that fosters collaboration between clinicians and basic scientists. The Foundation also supports training for new vision research scientists around the world.
For more information, please click here
Copyright © Association for Research in Vision and OphthalmologyIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Haydale Named Lead Sponsor for Cambridge Graphene Festival May 22nd, 2015
Directa Plus in Barcelona to present the innovative project GEnIuS for oil spills clean-up activities: The company has created a graphene-based product for the remediation of water contaminated by oil and hydrocarbons May 21st, 2015